<DOC>
	<DOCNO>NCT00879398</DOCNO>
	<brief_summary>The objective study determine problem question safety efficacy Toviaz® standard condition usage .</brief_summary>
	<brief_title>Toviaz Post Marketing Surveillance Study</brief_title>
	<detailed_description>continuous registration method</detailed_description>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Fesoterodine</mesh_term>
	<criteria>Subjects diagnose Overactive Bladder ( OAB ) define urgency , without urgency incontinence , usually frequency nocturia , absence local metabolic factor explain factor . Hypersensitivity active substance peanut soya excipients Urinary retention Gastric retention Uncontrolled narrow angle glaucoma Myasthenia gravis Severe hepatic impairment ( Child Pugh C ) Concomitant use potent CYP3A4 inhibitor subject moderate severe hepatic renal impairment Severe ulcerative colitis Toxic megacolon Patients rare hereditary problem galactose intolerance , Lapp lactase deficiency glucosegalactose malabsorption ( Toviaz® prolongedrelease tablet contain lactose )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>